Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection

• Published in: Clinical science (1979) Vol. 117; no. 5-6; pp. 191 - 200
• Main Authors: SHIMIZU, Mikiko, TROPAK, Michael, REDINGTON, Andrew N, DIAZ, Roberto J, SUTO, Fumiaki, SURENDRA, Harinee, KUZMIN, Elena, LI, Jing, GROSS, Gil, WILSON, Gregory J, CALLAHAN, John
• Format: Journal Article
• Language: English
• Published: London Portland Press 03.08.2009
• Subjects: Animals; Biological and medical sciences; Blood; Dialysis Solutions - pharmacology; General aspects; Hindlimb - blood supply; Humans; Ischemia; Ischemic Preconditioning, Myocardial - methods; Ligation; Medical sciences; Muscle, Skeletal - blood supply; Myocardial Infarction - pathology; Myocardial Infarction - prevention & control; Myocardial Reperfusion; Myocardial Reperfusion Injury - prevention & control; Myocardium; Myocytes, Cardiac - pathology; Naloxone - pharmacology; Narcotic Antagonists - pharmacology; Rabbits; Random Allocation; Receptors, Opioid - drug effects; Protein kinase C; remote ischaemic preconditioning; Enzyme; Transferases; Cross protection; opioid; Mitogen-activated protein kinase; limb ischaemia; mitogen-activated protein kinase (MAPK); Cardiovascular disease; Lower limb ischemia; Mechanism; Transitory; Vascular disease; Medicine; Cross immunity; protein kinase C (PKC); Myocardium; Circulatory system; Species; Preconditioning; Humoral immunity
• ISSN: 0143-5221; 1470-8736
• DOI: 10.1042/cs20080523

rIPC (remote ischaemic preconditioning) is a phenomenon whereby short periods of ischaemia and reperfusion of a tissue or organ (e.g. mesentery, kidney) can protect a distant tissue or organ (e.g. heart) against subsequent, potentially lethal, ischaemia. We, and others, have shown that transient limb ischaemia can provide potent myocardial protection experimentally and clinically during cardiac surgery. Nonetheless, our understanding of the signal transduction from remote stimulus to local effect remains incomplete. The aim of the present study was to define the humoral nature of rIPC effector(s) from limb ischaemia and to study their local effects in isolated heart and cardiomyocyte models. Using a Langendorff preparation, we show that infarct size after coronary artery ligation and reperfusion was substantially reduced by rIPC in vivo, this stimulus up-regulating the MAPKs (mitogen-activating protein kinases) p42/p44, and inducing PKCepsilon (protein kinase Cepsilon) subcellular redistribution. Pre-treatment with the plasma and dialysate of plasma (obtained using 15 kDa cut-off dialysis membrane) from donor rabbits subjected to rIPC similarly protected against infarction. The effectiveness of the rIPC dialysate was abrogated by passage through a C18 hydrophobic column, but eluate from this column provided the same level of protection. The dialysate of rIPC plasma from rabbits and humans was also tested in an isolated fresh cardiomyocyte model of simulated ischaemia and reperfusion. Necrosis in cardiomyocytes treated with rIPC dialysate was substantially reduced compared with control, and was similar to cells pre-treated by 'classical' preconditioning. This effect, by rabbit rIPC dialysate, was blocked by pre-treatment with the opiate receptor blocker naloxone. In conclusion, in vivo transient limb ischaemia releases a low-molecular-mass (<15 kDa) hydrophobic circulating factor(s) which induce(s) a potent protection against myocardial ischaemia/reperfusion injury in Langendorff-perfused hearts and isolated cardiomyocytes in the same species. This cardioprotection is transferable across species, independent of local neurogenic activity, and requires opioid receptor activation.